Highest-materiality recent filing
Ashland enters $500M five-year unsecured revolving credit facility
New credit agreement provides $500M revolver (incl. $125M LC sublimit), maturing May 28, 2031.
Ashland appoints Bertrand Loy (Entegris exec chair) to board, effective May 15, 2026
Bertrand Loy appointed independent director, increasing board to 9 members.
Ashland announces preliminary Q2 results; no financial details in filing
Preliminary second quarter results announced on April 28, 2026.
Ashland Q1 sales down 5% to $386M; narrows FY2026 EBITDA guidance to $400–420M
Net loss of $12M (($0.26)/diluted share); Adjusted EPS excl. intangibles amortization $0.26.
Ashland grants CEO Guillermo Novo $2M retention RSUs vesting Dec 2028
One-time award of RSUs with $2M value, cliff-vesting on December 31, 2028.
All eight director nominees elected; Jerome Peribere received 1.35M against (3.6% of cast) and 347K abstentions.
Ashland reports preliminary FY2025 Q4 and annual results, plus FY2026 outlook
Announcement made via press release on November 4, 2025; detailed figures not included in 8-K body text.
Director Sergio Pedreiro resigns from Ashland Board, effective Sept 30, 2025
Sergio Pedreiro resigned from Board, Compensation Committee and as Audit Committee Chair.
Ashland announces preliminary Q3 FY2025 results; specific figures not provided in filing text
Announcement made on July 29, 2025 via press release attached as Exhibit 99.1.
Ashland corrects CFO PSU vesting date from 2029 to 2028
Original 8-K (July 21, 2025) appointed William Whitaker as CFO with PSUs vesting Nov 20, 2029.
Ashland permanently appoints William Whitaker as CFO; base salary $414,600
William Whitaker permanently appointed SVP, CFO effective July 18, 2025; previously interim CFO since May 6.
Ashland SVP Operations Karl Bostaph to retire Oct 1; Wayne Muil named successor
Karl Bostaph, SVP Operations and named executive officer, will retire effective October 1, 2025.
Ashland CFO J. Kevin Willis resigns; Whitaker named interim CFO, Richardson as PAO
J. Kevin Willis resigns as SVP, CFO effective May 16, 2025 to pursue another opportunity; no disagreement with company.
Ashland announces preliminary Q2 FY2025 results; details absent from filing
Preliminary second-quarter results announced on April 30, 2025.
Ashland Q1 sales $405M (-14% YoY), net loss $165M; reiterates FY2025 outlook
Sales $405M, down 14% YoY; portfolio optimization cut 11% (excluding optimization, sales down 3%).
Ashland appoints J. Kevin Willis as Principal Accounting Officer and reports annual meeting results
J. Kevin Willis, SVP and CFO, also appointed Principal Accounting Officer effective January 21, 2025.
Ashland VP Finance and Principal Accounting Officer Eric Boni departs
Eric F. Boni, Ashland's VP Finance and Principal Accounting Officer, to depart after a brief transition period.
Ashland Q4 sales $522M (+1% YoY), adj. EBITDA $124M (+68%), issues FY2025 outlook
Sales $522M, up 1% YoY; nutraceuticals divestiture and CMC/MC curtailments reduced sales ~$24M (5%).
Ashland director Wetteny Joseph to not stand for reelection at 2025 annual meeting
Director Wetteny Joseph notified Ashland of his decision to not stand for reelection at the 2025 Annual Meeting.
Ashland amends receivables facility: size reduced to $80M, Fifth Third exits
Facility reduced to $80M through Dec 31, 2024 and $70M thereafter; previously $115M/$100M.
Ashland Q3 adjusted EBITDA up 5% to $139M; adjusted EPS $1.49 beats prior year $1.23
Sales $544M flat YoY; adjusted EBITDA $139M (+5%) on volume gains, favorable mix, and deflationary raw materials.
Ashland appoints Ashish K. Kulkarni to Board of Directors
Kulkarni elected as independent director effective May 6, 2024; board size increased to 11.
Ashland to sell nutraceuticals business to Turnspire; expects $110-120M impairment in Q3 FY2024
Signed definitive agreement to sell nutraceuticals business to Turnspire Capital Partners; closing expected calendar Q3 2024.
Ashland SVP and GM of Life Sciences and Intermediates resigns effective May 10, 2024
Ashok Kalyana resigns as SVP and GM of Life Sciences and Intermediates.
Sales $575M, down 5% YoY; net income $120M ($2.39 diluted), up from $91M.
Ashland appoints former Albemarle CFO Scott Tozier as independent director
Scott A. Tozier elected to Ashland board as independent director effective April 15, 2024.
Ashland SVP Min Chong to depart April 30, 2024 under severance plan
Min Chong, SVP and GM of Personal Care and Specialty Additives, will depart Ashland on April 30, 2024.
Ashland Q1 sales down 10% YoY to $473M; adj. EBITDA falls 35% to $70M
Net income from continuing ops $28M ($0.54 diluted EPS) vs $42M ($0.76) a year ago; adjusted EPS excl. intangibles $0.45 vs $0.97.
All nine director nominees elected with strong support; highest against vote was Jerome Peribere at ~1.34M against out of ~44M votes cast.
Ashland grants CEO Guillermo Novo $1M one-time equity award to retain him through 2026
One-time award target value $1,000,000: 60% performance units, 40% time-based RSUs.
Ashland appoints Merck EVP Sanat Chattopadhyay to board; two directors not seeking re-election
Sanat Chattopadhyay, executive vice president of Merck (MRK), joined Ashland board effective Nov. 13, 2023.
Ashland announces preliminary Q4 and FY2023 results and FY2024 outlook
Preliminary results for Q4 and fiscal year 2023 announced on November 8, 2023.
Ashland posts preliminary Q4 net loss of $4M; Adj. EBITDA $74M, below expectations
Preliminary Q4 sales $518M; full-year sales $2.19B. Net loss $4M in Q4, net income $178M in FY.
Ashland enters €125M three-year receivables securitization program
€125 million EU A/R Facility with three-year maturity; Bank of America as administrative agent.
Ashland amends 8-K; director Pedreiro joins Audit and Compensation Committees
Original 8-K date corrected from June 26, 2023 to June 22, 2023.
Ashland announces preliminary Q3 results; press release not provided in filing text
Preliminary third quarter results announced on July 25, 2023.
Ashland sees Q3 sales down ~15%, EBITDA down 22-25%; cuts FY23 outlook; announces $1B buyback
Preliminary Q3 sales expected $545-550M (down ~15% YoY); adjusted EBITDA $130-135M (down 22-25%).
Ashland board appoints Sergio Pedreiro as new director; Ihlenfeld and Cummins to exit January 2024
Sergio Pedreiro, former COO of Revlon, appointed to Ashland board effective July 1, 2023.
Ashland raises quarterly dividend 15% to $0.385, announces $100M share repurchase plan
Quarterly dividend increased 15% to $0.385 per share, payable June 15, 2023 to holders of record June 1, 2023.
Ashland announces preliminary Q2 FY2023 results; specifics not in filing text
Ashland announced preliminary second quarter fiscal 2023 results on May 2, 2023.
Facility limit raised to $115M for April-October and $100M otherwise; termination extended to April 14, 2025.
Ashland files 8-K/A correcting minor vote errors from Jan 24 annual meeting
Corrected vote counts for all director nominees; outcome unchanged.
Ashland Q1 sales $525M (+3% YoY), adj. EPS $0.97, EBITDA $108M, reaffirms FY guidance
Net income $40M ($0.73 diluted), income from continuing ops $42M ($0.76 diluted).
Ashland shareholders elect all nine director nominees at annual meeting
All nine director nominees elected; Steven D. Bishop received 46,108,846 votes for.
Prelim Q1 adjusted EPS $0.97; adjusted EBITDA $108M (+2% YoY, +15% constant-currency).
Ashland announces preliminary Q4 and FY2022 results with FY2023 outlook; details in press release
Preliminary Q4 and fiscal year 2022 results announced on Nov 7, 2022.
Ashland adopts proxy access bylaw allowing stockholders to nominate up to 20% of directors
New Section 3.16 permits eligible stockholders to include nominees in company proxy materials for board elections.
Ashland furnishes corporate presentation at Credit Suisse; no new financial details disclosed
Presentation dated September 14, 2022, given to Credit Suisse by CEO Guillermo Novo.
Ashland assigns Bishop and Harrison to board committees effective Aug 5
Steven D. Bishop appointed to Compensation Committee and Environmental, Health, Safety and Quality Committee.
Ashland Global Holdings changes name to Ashland Inc. effective August 1, 2022
Name change from Ashland Global Holdings Inc. to Ashland Inc. effective August 1, 2022.
On May 15, 2026, the Board of Directors (the “Board”) of Ashland Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Mr. Bertrand Loy to serve as an independent director on the Board, effective the same day.
On May 1, 2025, J. Kevin Willis notified Ashland Inc. (the “Company”) of his intention to resign as the Company’s Senior Vice President, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 16, 2025 (the “Effective Date”), to pursue another opportunity.
On May 5, 2025, the Company’s Board of Directors (the “Board”) appointed William C. Whitaker, the Company’s Vice President, Finance and Director, Investor Relations, to serve as the Company’s Interim Chief Financial Officer, effective May 6, 2025.
On May 5, 2025, the Board also appointed Samuel A. Richardson, the Company’s Controller, to serve as Vice President, Controller and Principal Accounting Officer of the Company, effective May 6, 2025.
On January 21, 2025, the Board of Directors of Ashland Inc. (“Ashland” or the “Company”) appointed J. Kevin Willis, the Company’s Senior Vice President, Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer, effective January 21, 2025.
On November 19, 2024, Ashland Inc (the “Company”) and Eric F. Boni, the Company’s Vice President, Finance and Principal Accounting Officer, agreed that Mr. Boni will depart from the Company following a brief transition period.
On October 30, 2024, Wetteny Joseph, a member of the Board of Directors (the “Board”) of Ashland Inc. (the “Company”), notified the Company of his decision to not stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On May 6, 2024, the Board of Directors (“Board”) of Ashland Inc. (“Company”) elected Ashish K. Kulkarni, to the Board to serve as an independent director, and also appointed him to serve as a member of the Board's Environmental, Health, Safety, and Quality Committee and the Compensation Committee, in each case effective May 6, 2024.
On April 29, 2024, Ashok Kalyana submitted his resignation from his role as Senior Vice President, and General Manager, Life Sciences and Intermediates of Ashland Inc. effective May 10, 2024.
On April 10, 2024, the Board of Directors (“Board”) of Ashland Inc. (“Company”) elected Scott A. Tozier to the Board to serve as an independent director, and also appointed him to serve as a member of the Board's Audit Committee and the Environmental, Health, Safety, and Quality Committee, in each case effective April 15, 2024.
On February 20, 2024, Ashland Inc. (the “Company”) and Min Chong, the Company’s Senior Vice President and General Manager, Personal Care and Specialty Additives, agreed that Mr. Chong will depart from the Company on April 30, 2024.
On November 13, 2023, the Board of Directors (“Board”) of Ashland Inc. (“Company”) elected Sanat Chattopadhyay to the Board to serve as an independent director
Max materiality 0.80 · Median 0.40 · Most common event earnings